Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | BRCA and RAB: prognostic biomarkers in recurrent ovarian cancer

Elizabeth Swisher • 19 May 2020
ASCO 2020
Gynecological Cancer Ovarian Cancer Rucaparib

Elizabeth Swisher, MD, Seattle Cancer Care Alliance, University of Washington Medical Center, Seattle, WA, discusses the mutational status of BRCA and RAB proteins and how this can be used prognostically as a biomarker for long-term durable responses to rucaparib treatment in recurrent ovarian cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Elizabeth Swisher

1:26
EDGE: increasing hereditary cancer screening rates in primary care
Elizabeth Swisher • 7 Apr 2024
0:49
Remotely delivered cancer genetic testing in the Making Genetic Testing Accessible (MAGENTA) trial
Elizabeth Swisher • 7 Apr 2024
0:37
Hematopoiesis in ovarian cancer survivors to determine risk of secondary blood cancers
Elizabeth Swisher • 7 Apr 2024
0:35
Phase I dose expansion results of CYT-0851 plus capecitabine in platinum-resistant ovarian cancer
Elizabeth Swisher • 7 Apr 2024

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals